FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085559668> ?p ?o ?g. }

• W2085559668 endingPage "246" @default.
• W2085559668 startingPage "245" @default.
• W2085559668 abstract "Low bone mineral density (BMD) and osteoporosis are prevalent in HIV-infected men. Teriparatide – a human recombinant parathyroid hormone – is used to treat severe osteoporosis; however, its use has not been reported in HIV-infected men. A 70-year-old HIV-infected man presented with lower back pain after carrying heavy furniture and was found to have L1 and L2 compression fractures. Osteoporosis was confirmed on dual-energy X-ray absorptiometry (DXA) with T-scores of −3.9 (BMD = 0.606 g/cm2) at the lumbar spine, −2.6 (0.643 g/cm2) at the total hip, and −2.8 (0.552 g/cm2) at the femoral neck (Table 1).Table 1: Yearly change in bone mineral density with treatment.The patient had well controlled HIV (CD4+ cell count: 880 cells/ml; undetectable HIV viral load) on tenofovir (TDF)/emtricitabine and atazanavir/ritonavir. He reported a family history of osteoporosis, a 40 pack-years history of tobacco use, and heavy alcohol consumption (>3 drinks daily). Pertinent biochemical studies revealed hypogonadism (morning testosterone level: 116.8 ng/dl), vitamin D deficiency [25-hydroxyvitamin D (25OHD) level: 14.5 ng/ml), and low urinary calcium excretion (<34 mg/day). Given his severely low BMD, especially at the lumbar spine, therapy with teriparatide was initiated for 24 months with subsequent consolidative therapy with alendronate. At the end of year 2, the BMD had increased significantly, with T-scores −2.8 at the lumbar spine, −2.4 at the total hip, and −2.3 at the femoral neck. Compared to baseline, the relative BMD increases at the lumbar spine, total hip, and femoral neck were 35.4, 3.5, and 12.5%, respectively. By the end of year 3, his BMD increased to a T-score of −2.4 at the lumbar spine, with relatively more robust increases to −1.9 and −2.3 at the total hip and femoral neck, respectively. Among HIV-infected men, the cause of osteoporosis may be multifactorial. Risk factors for osteoporosis such as hypogonadism, vitamin D deficiency, smoking, and low body weight are more common in HIV-infected men than uninfected men. The direct effects of antiretroviral therapy may also play a role. An association has been reported between TDF, which this patient received, and lower BMD. Through alterations in renal phosphate handling, TDF impairs bone mineralization while increasing bone turnover and osteomalacia. These effects may be more pronounced in vitamin D deficiency [1,2]. Although this patient did not have documented renal phosphate wasting, TDF was switched to abacavir as a precaution. Screening and treatment guidelines in HIV have typically followed those determined for the general population; however, McComsey et al.[3] recommended a screening DXA scan for all HIV-infected men aged at least 50 years. If osteoporosis is identified, men should be screened and treated for secondary causes, as was done in our patient. He was offered testosterone replacement for his hypogonadism and started on calcium and vitamin D supplements due to his low urinary calcium excretion and vitamin D deficiency. HIV-infected men on TDF should also undergo assessment for renal phosphate wasting by calculating the fractional excretion of phosphate using simultaneous measurements of serum and urine phosphate and creatinine [1]. Pharmacologic treatment of osteoporosis should be considered for men aged at least 50 years with hip or vertebral fractures or BMD T-score −2.5 or less at the femoral neck, total hip, or lumbar spine. Considerations should also be made for treatment if the lowest T-score is −1.0 to −2.5 (i.e. ‘osteopenia’) and the 10-year probability of hip fracture at least 3% or major osteoporosis-related fracture at least 20% based on the US Fracture Risk Assessment Tool (FRAX) [5]. However, FRAX has not been validated in HIV-infected men and may underestimate the risk of fracture in these patients [3]. Teriparatide increases BMD by recruiting osteoblast progenitor cells and directly stimulating mature osteoblasts. US Food and Drug Administration (US FDA) approval is for up to 2 years of use, and antiresorptive therapy, generally with a bisphosphonate, is recommended for consolidation as BMD declines quickly once teriparatide treatment has concluded [6]. Teriparatide preferentially increases BMD at the lumbar spine, a site rich in trabecular bone, over the total hip and femoral neck, where it has more modest effects. Thus, one of the recommended uses for teriparatide is for severely reduced BMD, especially at the lumbar spine. This applied to our patient. Trials have demonstrated a reduction in vertebral fractures that is most pronounced in men with pre-existing fractures [4]. Teriparatide does not carry a risk of esophagitis, atypical femoral fractures, or osteonecrosis of the jaw, which can be seen rarely with bisphosphonates. However, patients on teriparatide should be monitored for hypercalcemia and hypercalciuria, which are the most common side effects. To our knowledge, this is the first case report highlighting teriparatide's efficacy in treating osteoporosis in the setting of HIV infection. Investigation is warranted to determine whether teriparatide reduces fracture incidence in HIV-infected individuals. Acknowledgements Grant support: Supported by National Institutes of Health, through 5K12HD052163-15 and by the National Center for Advancing Translational Sciences of the NIH under Award Number KL2TR000143. The manuscript contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Conflicts of interest There are no conflicts of interest. Disclosures: A.L.W., P.C.T., C.G., and A.L.S. have no potential conflicts of interest to disclose." @default.
• W2085559668 created "2016-06-24" @default.
• W2085559668 creator A5002438645 @default.
• W2085559668 creator A5048434963 @default.
• W2085559668 creator A5072034096 @default.
• W2085559668 creator A5084163106 @default.
• W2085559668 date "2015-01-14" @default.
• W2085559668 modified "2023-09-27" @default.
• W2085559668 title "Teriparatide treatment of osteoporosis in an HIV-infected man" @default.
• W2085559668 cites W2075195284 @default.
• W2085559668 cites W2093809946 @default.
• W2085559668 cites W2114323760 @default.
• W2085559668 cites W2127597063 @default.
• W2085559668 cites W2142900141 @default.
• W2085559668 cites W2319373208 @default.
• W2085559668 doi "https://doi.org/10.1097/qad.0000000000000529" @default.
• W2085559668 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4438749" @default.
• W2085559668 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25532609" @default.
• W2085559668 hasPublicationYear "2015" @default.
• W2085559668 type Work @default.
• W2085559668 sameAs 2085559668 @default.
• W2085559668 citedByCount "17" @default.
• W2085559668 countsByYear W20855596682015 @default.
• W2085559668 countsByYear W20855596682016 @default.
• W2085559668 countsByYear W20855596682017 @default.
• W2085559668 countsByYear W20855596682018 @default.
• W2085559668 countsByYear W20855596682019 @default.
• W2085559668 countsByYear W20855596682020 @default.
• W2085559668 countsByYear W20855596682021 @default.
• W2085559668 countsByYear W20855596682023 @default.
• W2085559668 crossrefType "journal-article" @default.
• W2085559668 hasAuthorship W2085559668A5002438645 @default.
• W2085559668 hasAuthorship W2085559668A5048434963 @default.
• W2085559668 hasAuthorship W2085559668A5072034096 @default.
• W2085559668 hasAuthorship W2085559668A5084163106 @default.
• W2085559668 hasBestOaLocation W20855596681 @default.
• W2085559668 hasConcept C124490489 @default.
• W2085559668 hasConcept C126322002 @default.
• W2085559668 hasConcept C126894567 @default.
• W2085559668 hasConcept C141071460 @default.
• W2085559668 hasConcept C142462285 @default.
• W2085559668 hasConcept C203014093 @default.
• W2085559668 hasConcept C2775854910 @default.
• W2085559668 hasConcept C2776541429 @default.
• W2085559668 hasConcept C2776886416 @default.
• W2085559668 hasConcept C2777308945 @default.
• W2085559668 hasConcept C2778414717 @default.
• W2085559668 hasConcept C2779329777 @default.
• W2085559668 hasConcept C2779809032 @default.
• W2085559668 hasConcept C2993143319 @default.
• W2085559668 hasConcept C3013748606 @default.
• W2085559668 hasConcept C71924100 @default.
• W2085559668 hasConceptScore W2085559668C124490489 @default.
• W2085559668 hasConceptScore W2085559668C126322002 @default.
• W2085559668 hasConceptScore W2085559668C126894567 @default.
• W2085559668 hasConceptScore W2085559668C141071460 @default.
• W2085559668 hasConceptScore W2085559668C142462285 @default.
• W2085559668 hasConceptScore W2085559668C203014093 @default.
• W2085559668 hasConceptScore W2085559668C2775854910 @default.
• W2085559668 hasConceptScore W2085559668C2776541429 @default.
• W2085559668 hasConceptScore W2085559668C2776886416 @default.
• W2085559668 hasConceptScore W2085559668C2777308945 @default.
• W2085559668 hasConceptScore W2085559668C2778414717 @default.
• W2085559668 hasConceptScore W2085559668C2779329777 @default.
• W2085559668 hasConceptScore W2085559668C2779809032 @default.
• W2085559668 hasConceptScore W2085559668C2993143319 @default.
• W2085559668 hasConceptScore W2085559668C3013748606 @default.
• W2085559668 hasConceptScore W2085559668C71924100 @default.
• W2085559668 hasIssue "2" @default.
• W2085559668 hasLocation W20855596681 @default.
• W2085559668 hasLocation W20855596682 @default.
• W2085559668 hasLocation W20855596683 @default.
• W2085559668 hasLocation W20855596684 @default.
• W2085559668 hasLocation W20855596685 @default.
• W2085559668 hasOpenAccess W2085559668 @default.
• W2085559668 hasPrimaryLocation W20855596681 @default.
• W2085559668 hasRelatedWork W2027977119 @default.
• W2085559668 hasRelatedWork W2041906538 @default.
• W2085559668 hasRelatedWork W2048415538 @default.
• W2085559668 hasRelatedWork W2083011022 @default.
• W2085559668 hasRelatedWork W2093371799 @default.
• W2085559668 hasRelatedWork W2320488177 @default.
• W2085559668 hasRelatedWork W2556881885 @default.
• W2085559668 hasRelatedWork W2791513707 @default.
• W2085559668 hasRelatedWork W2944555612 @default.
• W2085559668 hasRelatedWork W3043023029 @default.
• W2085559668 hasVolume "29" @default.
• W2085559668 isParatext "false" @default.
• W2085559668 isRetracted "false" @default.
• W2085559668 magId "2085559668" @default.
• W2085559668 workType "article" @default.